Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Latest filing published 10 Jul 2026 for AN2 Therapeutics, Inc., €22k. Read the official filing
Filing timeline
BuySaleJoshua M. Eizen
Insider track record
Disclosed buys
0
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Joshua M. Eizen: trading record in brief
Joshua M. Eizen discloses dealings in AN2 Therapeutics, Inc. to SEC (Form 4). Over a trading history stretching from 15 March 2024 to 8 July 2026, the count stands at 10 filings.
Sales make up the whole of the open-market record (4 sales, €52k). Outside the open market, there are 6 share grants. 2026 to date brings no purchases and 2 sales.
The latest filing, published on 10 July 2026, reports an open-market sale of €22k in AN2 Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Joshua M. Eizen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations10 total
5,945 shares@ US$4.172Common StockSEC:0001193125-26-301092:0
50,000 shares0Common StockSEC:0001193125-26-064176:0
17,923 shares@ US$1.0014Common StockSEC:0001193125-26-006763:0
2,819 shares@ US$1.1418.1% of flowCommon StockSEC:0001193125-25-270255:0
58,500 shares0Common StockSEC:0000950170-25-030042:0
9,663 shares@ US$1.341100.0% of flowCommon StockSEC:0000950170-25-003152:0
31,500 shares0Common StockSEC:0000950170-24-121591:0
60,000 shares0Common StockSEC:0000950170-24-083200:0
30,000 shares0Common StockSEC:0001610717-24-000194:0
30,000 shares0Common StockSEC:0001610717-24-000168:0
10 of 10 declarations
